ReviewBiomaterials research2018
New opportunities for nanoparticles in cancer immunotherapy.
Review in Biomaterials research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 214 citations in OpenAlex.
- Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen.International journal of molecular sciences · 2021Pooled it
- Metal oxide nanoparticles: emerging stars in biomedical application.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- Development of nanoparticle-based Toll-like receptor agonists for respiratory immunotherapy.EXCLI journal · 2026Review
- Advancements in Nanoparticle-Based Therapies for Breast Cancer: Current Trends and Future Prospects.International journal of breast cancer · 2026Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- Decoding the Tumor Microenvironment: Insights and New Targets from Single-Cell Sequencing and Spatial Transcriptomics.Current issues in molecular biology · 2025Review
- Chitosan Microparticles Coupled with MAGE-AX and CpGs as a Treatment for Murine Melanoma.Pharmaceutics · 2025Article
- Enhancing bevacizumab efficacy in a colorectal tumor mice model using dextran-coated albumin nanoparticles.Drug delivery and translational research · 2025Article
- GSH/pH-responsive copper-based cascade nanocomplexes inducing immunogenic cell death through cuproptosis/ferroptosis/necroptosis in oral squamous cell carcinoma.Materials today. Bio · 2025Article
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Recent Insights Into Breast Cancer: Molecular Pathways, Epigenetic Regulation, and Emerging Targeted Therapies.Breast cancer : basic and clinical research · 2025Review
- Nanoemulsions in Skin Cancer Therapy: A Promising Frontier.Current pharmaceutical biotechnology · 2025Review
- Advanced Targeted Drug Delivery of Bioactive Agents Fortified with Graft Chitosan in Management of Cancer: A Review.Current medicinal chemistry · 2025Review
- Smart Multifunctional Nanoparticles in Cancer Theranostics: Progress and Prospect.Pharmaceutical nanotechnology · 2025Review
- Analysis of the mechanisms underlying the anticancer and biological activity of retinoic acid and chitosan nanoparticles containing retinoic acid.Medical oncology (Northwood, London, England) · 2024Article
- Recent Advances in the Development and Utilization of Nanoparticles for the Management of Malignant Solid Tumors.Cureus · 2024Review
- Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.Advanced healthcare materials · 2024Review
- Anti-Cancer Activities of Nano Amorphous Calcium Phosphates toward Premalignant and Oral Cancer Cells.Biomedicines · 2024Article
- M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy.Acta pharmaceutica Sinica. B · 2024Article
- Folic acid-modified nanocrystalline cellulose for enhanced delivery and anti-cancer effects of crocin.Scientific reports · 2024Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, cancer immunotherapy has become standard for cancer treatment. Immunotherapy not only treats primary tumors, but also prevents metastasis and recurrence, representing a major advantage over conventional cancer treatments. However, existing cancer immunotherapies have limited clinical benefits because cancer antigens are often not effectively delivered to immune cells. Furthermore, unlike lymphoma, solid tumors evade anti-cancer immunity by forming an immune-suppressive tumor microenvironment (TME). One approach for overcoming these limitations of cancer immunotherapy involves nanoparticles based on biomaterials. MAIN BODY: Here, we review in detail recent trends in the use of nanoparticles in cancer immunotherapy. First, to illustrate the unmet needs for nanoparticles in this field, we describe the mechanisms underlying cancer immunotherapy. We then explain the role of nanoparticles in the delivery of cancer antigens and adjuvants. Next, we discuss how nanoparticles can be helpful within the immune-suppressive TME. Finally, we summarize current and future uses of nanoparticles with image-guided interventional techniques in cancer immunotherapy.
conclusionRecently developed approaches for using nanoparticles in cancer immunotherapy have enormous potential for improving cancer treatment. Cancer immunotherapy based on nanoparticles is anticipated not only to overcome the limitations of existing immunotherapy, but also to generate synergistic effects via cooperation between nanoparticles and immune cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.